[Comorbidities and concomitant medication use in adult patients with chronic hepatitis C: a descriptive epidemiological analysis].

Objective: To analyze the comorbidity and concomitant medications use in adult patients with chronic hepatitis C. Methods: A descriptive epidemiological methods was carried out in adult patients with chronic hepatitis C and data from 2013 to 2015 were accessed through the China Medical Insurance database. Results: Among a chronic HCV cohort of 2 958 cases, the top five comorbidities were diabetes, hypertension, ischemic heart disease, gastroduodenitis, and co-infection with HBV and HCV. The three most common concomitant medications prescribed for mentioned comorbidities were acarbose, metformin and repaglinide (Diabetes), nifedipine, amlodipine and metoprolol (Hypertension), aspirin, nifedipine and amlodipine (Ischemic heart disease), omeprazole, pantoprazole and levolfoxacin (Gastroduodenitis), ribavirin, pegylated interferon alpha-2a and alpha-2b ( Co- infected with hepatitis B and C virus). Conclusion: The five most frequent comorbidities in adult patients with chronic hepatitis C are diabetes, hypertension, ischemic heart disease, gastroduodenitis, and co-infection with HBV and HCV. A concomitant medication use in those patients with comorbidities causes potential drug-drug interactions.目的： 分析2013至2015年中国城镇医疗保险中慢性丙型肝炎患者合并其他疾病及合并其他疾病用药情况，为合并不同疾病的慢性丙型肝炎药物选择提供依据。 方法： 采用描述性流行病学研究方法，分析中国医疗保险数据库中2013至2015年慢性丙型肝炎患者资料。 结果： 2013至2015年慢性丙型肝炎患者共2 958例，慢性丙型肝炎患者合并疾病排名前5位为：糖尿病、高血压、冠心病、胃十二指肠炎和慢性乙型肝炎。合并用药中：合并糖尿病患者用药前3位为阿卡波糖、二甲双胍和瑞格列奈；合并高血压患者用药前3位为氨氯地平、硝苯地平和美托洛尔；合并冠心病患者用药前3位为阿司匹林、氨氯地平和硝苯地平；合并胃十二指肠炎患者用药前3位为奥美拉唑、左氧氟沙星和泮托拉唑；乙型与丙型肝炎共感染患者用药前3位为利巴韦林、聚乙二醇干扰素α-2a和α-2b。 结论： 丙型肝炎患者合并疾病排名前5位为：糖尿病、高血压、冠心病、胃十二指肠炎和慢性乙型肝炎。各合并疾病用药基本符合规范但可能存在与慢性丙型肝炎直接抗病毒药物的药物相互作用。.